{"id":23180,"date":"2022-03-31T18:54:34","date_gmt":"2022-03-31T18:54:34","guid":{"rendered":"https:\/\/sbpt.org.br\/portal\/?p=23180"},"modified":"2022-03-31T18:54:34","modified_gmt":"2022-03-31T18:54:34","slug":"anvisa-sotorasibe","status":"publish","type":"post","link":"https:\/\/sbpt.org.br\/portal\/anvisa-sotorasibe\/","title":{"rendered":"Anvisa aprova inibidor de muta\u00e7\u00f5es de KRAS G12C para c\u00e2ncer de pulm\u00e3o"},"content":{"rendered":"<p style=\"text-align: justify\">A Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria (Anvisa) aprovou o sotorasibe para tratamento do c\u00e2ncer de pulm\u00e3o de n\u00e3o pequenas c\u00e9lulas com muta\u00e7\u00e3o de KRAS G12C.<\/p>\n<p style=\"text-align: justify\">A terapia-alvo \u00e9 indicada para pacientes com CPNPC com muta\u00e7\u00e3o de KRAS G12C expostos a pelo menos uma linha de tratamento sist\u00eamico pr\u00e9vio.<\/p>\n<p style=\"text-align: justify\">Atualmente, h\u00e1 outras formas de quimioterapia oral para pacientes selecionados, conforme as muta\u00e7\u00f5es se apresentem.<\/p>\n<p style=\"text-align: justify\">Em um estudo cl\u00ednico de coorte fase II, a taxa de resposta a sotorasibe foi de 37,1% entre 124 pacientes, incluindo 3,2% de respostas completas. A dura\u00e7\u00e3o da resposta ao tratamento foi de 11,1 meses.\u00b9<\/p>\n<p>A dose de tratamento recomendada \u00e9 de 960 mg, via oral, uma vez ao dia.<\/p>\n<p style=\"text-align: justify\">A taxa de controle de doen\u00e7a foi de 80,6%. Na avalia\u00e7\u00e3o de seguran\u00e7a, 20,6% dos pacientes apresentaram eventos adversos de graus \u2265 3.<\/p>\n<p>Refer\u00eancias<\/p>\n<p style=\"text-align: justify\">Skoulidis F, et al. <a href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2103695\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>Sotorasib for Lung Cancers with KRAS p.G12C Mutation<\/strong><\/a>. N Engl J Med. 2021 Jun 24;384(25):2371-2381. doi: 10.1056\/NEJMoa2103695. Epub 2021 Jun 4. PMID: 34096690.<\/p>\n<p style=\"text-align: justify\">Schiavon, Fabiana. <strong><a href=\"https:\/\/saude.abril.com.br\/medicina\/medicamento-inovador-contra-cancer-de-pulmao-e-aprovado-pela-anvisa\/\" target=\"_blank\" rel=\"noopener noreferrer\">Medicamento inovador contra c\u00e2ncer de pulm\u00e3o \u00e9 aprovado pela Anvisa<\/a><\/strong>. Revista Sa\u00fade, mar 2022. Dispon\u00edvel em: https:\/\/saude.abril.com.br\/medicina\/medicamento-inovador-contra-cancer-de-pulmao-e-aprovado-pela-anvisa\/. Acesso em 31 mar 2022.<\/p>\n<!-- AddThis Advanced Settings generic via filter on the_content --><!-- AddThis Share Buttons generic via filter on the_content -->","protected":false},"excerpt":{"rendered":"<p>A Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria (Anvisa) aprovou o sotorasibe para tratamento do c\u00e2ncer de pulm\u00e3o de n\u00e3o pequenas c\u00e9lulas com muta\u00e7\u00e3o de KRAS G12C. A terapia-alvo \u00e9 indicada para pacientes com CPNPC com muta\u00e7\u00e3o de KRAS G12C expostos a pelo menos uma linha de tratamento sist\u00eamico pr\u00e9vio. Atualmente, h\u00e1 outras formas de quimioterapia oral [&hellip;]<!-- AddThis Advanced Settings generic via filter on get_the_excerpt --><!-- AddThis Share Buttons generic via filter on get_the_excerpt --><\/p>\n","protected":false},"author":3,"featured_media":22168,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"ngg_post_thumbnail":0,"footnotes":""},"categories":[68],"tags":[357,230,1101],"class_list":["post-23180","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-noticias","tag-anvisa","tag-cancer-de-pulmao","tag-sotorasibe"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Anvisa aprova inibidor de muta\u00e7\u00f5es de KRAS G12C para c\u00e2ncer de pulm\u00e3o - sbpt.org.br<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/sbpt.org.br\/portal\/anvisa-sotorasibe\/\" \/>\n<meta property=\"og:locale\" content=\"pt_BR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Anvisa aprova inibidor de muta\u00e7\u00f5es de KRAS G12C para c\u00e2ncer de pulm\u00e3o - sbpt.org.br\" \/>\n<meta property=\"og:description\" content=\"A Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria (Anvisa) aprovou o sotorasibe para tratamento do c\u00e2ncer de pulm\u00e3o de n\u00e3o pequenas c\u00e9lulas com muta\u00e7\u00e3o de KRAS G12C. A terapia-alvo \u00e9 indicada para pacientes com CPNPC com muta\u00e7\u00e3o de KRAS G12C expostos a pelo menos uma linha de tratamento sist\u00eamico pr\u00e9vio. Atualmente, h\u00e1 outras formas de quimioterapia oral [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/sbpt.org.br\/portal\/anvisa-sotorasibe\/\" \/>\n<meta property=\"og:site_name\" content=\"sbpt.org.br\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/pneumosbpt\" \/>\n<meta property=\"article:published_time\" content=\"2022-03-31T18:54:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/sbpt.org.br\/portal\/wp-content\/uploads\/2021\/11\/lungs-destaques.png\" \/>\n\t<meta property=\"og:image:width\" content=\"350\" \/>\n\t<meta property=\"og:image:height\" content=\"255\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Comunica\u00e7\u00e3o SBPT\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@pneumosbpt\" \/>\n<meta name=\"twitter:site\" content=\"@pneumosbpt\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Comunica\u00e7\u00e3o SBPT\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. tempo de leitura\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minuto\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/sbpt.org.br\\\/portal\\\/anvisa-sotorasibe\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/sbpt.org.br\\\/portal\\\/anvisa-sotorasibe\\\/\"},\"author\":{\"name\":\"Comunica\u00e7\u00e3o SBPT\",\"@id\":\"https:\\\/\\\/sbpt.org.br\\\/portal\\\/#\\\/schema\\\/person\\\/adba7f33cf32721354590c6f0eb852d4\"},\"headline\":\"Anvisa aprova inibidor de muta\u00e7\u00f5es de KRAS G12C para c\u00e2ncer de pulm\u00e3o\",\"datePublished\":\"2022-03-31T18:54:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/sbpt.org.br\\\/portal\\\/anvisa-sotorasibe\\\/\"},\"wordCount\":217,\"publisher\":{\"@id\":\"https:\\\/\\\/sbpt.org.br\\\/portal\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/sbpt.org.br\\\/portal\\\/anvisa-sotorasibe\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/sbpt.org.br\\\/portal\\\/wp-content\\\/uploads\\\/2021\\\/11\\\/lungs-destaques.png\",\"keywords\":[\"ANVISA\",\"c\u00e2ncer de pulm\u00e3o\",\"sotorasibe\"],\"articleSection\":[\"Not\u00edcias\"],\"inLanguage\":\"pt-BR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/sbpt.org.br\\\/portal\\\/anvisa-sotorasibe\\\/\",\"url\":\"https:\\\/\\\/sbpt.org.br\\\/portal\\\/anvisa-sotorasibe\\\/\",\"name\":\"Anvisa aprova inibidor de muta\u00e7\u00f5es de KRAS G12C para c\u00e2ncer de pulm\u00e3o - sbpt.org.br\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/sbpt.org.br\\\/portal\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/sbpt.org.br\\\/portal\\\/anvisa-sotorasibe\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/sbpt.org.br\\\/portal\\\/anvisa-sotorasibe\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/sbpt.org.br\\\/portal\\\/wp-content\\\/uploads\\\/2021\\\/11\\\/lungs-destaques.png\",\"datePublished\":\"2022-03-31T18:54:34+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/sbpt.org.br\\\/portal\\\/anvisa-sotorasibe\\\/#breadcrumb\"},\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/sbpt.org.br\\\/portal\\\/anvisa-sotorasibe\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/sbpt.org.br\\\/portal\\\/anvisa-sotorasibe\\\/#primaryimage\",\"url\":\"https:\\\/\\\/sbpt.org.br\\\/portal\\\/wp-content\\\/uploads\\\/2021\\\/11\\\/lungs-destaques.png\",\"contentUrl\":\"https:\\\/\\\/sbpt.org.br\\\/portal\\\/wp-content\\\/uploads\\\/2021\\\/11\\\/lungs-destaques.png\",\"width\":350,\"height\":255},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/sbpt.org.br\\\/portal\\\/anvisa-sotorasibe\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/sbpt.org.br\\\/portal\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Anvisa aprova inibidor de muta\u00e7\u00f5es de KRAS G12C para c\u00e2ncer de pulm\u00e3o\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/sbpt.org.br\\\/portal\\\/#website\",\"url\":\"https:\\\/\\\/sbpt.org.br\\\/portal\\\/\",\"name\":\"sbpt.org.br\",\"description\":\"Sociedade Brasileira de Pneumologia e Tisiologia\",\"publisher\":{\"@id\":\"https:\\\/\\\/sbpt.org.br\\\/portal\\\/#organization\"},\"alternateName\":\"SBPT\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/sbpt.org.br\\\/portal\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pt-BR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/sbpt.org.br\\\/portal\\\/#organization\",\"name\":\"sbpt.org.br\",\"url\":\"https:\\\/\\\/sbpt.org.br\\\/portal\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/sbpt.org.br\\\/portal\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/sbpt.org.br\\\/portal\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/logo-sbpt.png\",\"contentUrl\":\"https:\\\/\\\/sbpt.org.br\\\/portal\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/logo-sbpt.png\",\"width\":512,\"height\":512,\"caption\":\"sbpt.org.br\"},\"image\":{\"@id\":\"https:\\\/\\\/sbpt.org.br\\\/portal\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/pneumosbpt\",\"https:\\\/\\\/x.com\\\/pneumosbpt\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/pneumosbpt\\\/\",\"https:\\\/\\\/www.instagram.com\\\/pneumosbpt\\\/\",\"https:\\\/\\\/www.youtube.com\\\/user\\\/socbraspneumol\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/sbpt.org.br\\\/portal\\\/#\\\/schema\\\/person\\\/adba7f33cf32721354590c6f0eb852d4\",\"name\":\"Comunica\u00e7\u00e3o SBPT\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/83068fab2f784f5c487104783a7006fb40e8fd85adc44189ac928b9e39fddad8?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/83068fab2f784f5c487104783a7006fb40e8fd85adc44189ac928b9e39fddad8?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/83068fab2f784f5c487104783a7006fb40e8fd85adc44189ac928b9e39fddad8?s=96&d=mm&r=g\",\"caption\":\"Comunica\u00e7\u00e3o SBPT\"},\"url\":\"https:\\\/\\\/sbpt.org.br\\\/portal\\\/author\\\/anahelena\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Anvisa aprova inibidor de muta\u00e7\u00f5es de KRAS G12C para c\u00e2ncer de pulm\u00e3o - sbpt.org.br","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/sbpt.org.br\/portal\/anvisa-sotorasibe\/","og_locale":"pt_BR","og_type":"article","og_title":"Anvisa aprova inibidor de muta\u00e7\u00f5es de KRAS G12C para c\u00e2ncer de pulm\u00e3o - sbpt.org.br","og_description":"A Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria (Anvisa) aprovou o sotorasibe para tratamento do c\u00e2ncer de pulm\u00e3o de n\u00e3o pequenas c\u00e9lulas com muta\u00e7\u00e3o de KRAS G12C. A terapia-alvo \u00e9 indicada para pacientes com CPNPC com muta\u00e7\u00e3o de KRAS G12C expostos a pelo menos uma linha de tratamento sist\u00eamico pr\u00e9vio. Atualmente, h\u00e1 outras formas de quimioterapia oral [&hellip;]","og_url":"https:\/\/sbpt.org.br\/portal\/anvisa-sotorasibe\/","og_site_name":"sbpt.org.br","article_publisher":"https:\/\/www.facebook.com\/pneumosbpt","article_published_time":"2022-03-31T18:54:34+00:00","og_image":[{"width":350,"height":255,"url":"https:\/\/sbpt.org.br\/portal\/wp-content\/uploads\/2021\/11\/lungs-destaques.png","type":"image\/png"}],"author":"Comunica\u00e7\u00e3o SBPT","twitter_card":"summary_large_image","twitter_creator":"@pneumosbpt","twitter_site":"@pneumosbpt","twitter_misc":{"Escrito por":"Comunica\u00e7\u00e3o SBPT","Est. tempo de leitura":"1 minuto"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/sbpt.org.br\/portal\/anvisa-sotorasibe\/#article","isPartOf":{"@id":"https:\/\/sbpt.org.br\/portal\/anvisa-sotorasibe\/"},"author":{"name":"Comunica\u00e7\u00e3o SBPT","@id":"https:\/\/sbpt.org.br\/portal\/#\/schema\/person\/adba7f33cf32721354590c6f0eb852d4"},"headline":"Anvisa aprova inibidor de muta\u00e7\u00f5es de KRAS G12C para c\u00e2ncer de pulm\u00e3o","datePublished":"2022-03-31T18:54:34+00:00","mainEntityOfPage":{"@id":"https:\/\/sbpt.org.br\/portal\/anvisa-sotorasibe\/"},"wordCount":217,"publisher":{"@id":"https:\/\/sbpt.org.br\/portal\/#organization"},"image":{"@id":"https:\/\/sbpt.org.br\/portal\/anvisa-sotorasibe\/#primaryimage"},"thumbnailUrl":"https:\/\/sbpt.org.br\/portal\/wp-content\/uploads\/2021\/11\/lungs-destaques.png","keywords":["ANVISA","c\u00e2ncer de pulm\u00e3o","sotorasibe"],"articleSection":["Not\u00edcias"],"inLanguage":"pt-BR"},{"@type":"WebPage","@id":"https:\/\/sbpt.org.br\/portal\/anvisa-sotorasibe\/","url":"https:\/\/sbpt.org.br\/portal\/anvisa-sotorasibe\/","name":"Anvisa aprova inibidor de muta\u00e7\u00f5es de KRAS G12C para c\u00e2ncer de pulm\u00e3o - sbpt.org.br","isPartOf":{"@id":"https:\/\/sbpt.org.br\/portal\/#website"},"primaryImageOfPage":{"@id":"https:\/\/sbpt.org.br\/portal\/anvisa-sotorasibe\/#primaryimage"},"image":{"@id":"https:\/\/sbpt.org.br\/portal\/anvisa-sotorasibe\/#primaryimage"},"thumbnailUrl":"https:\/\/sbpt.org.br\/portal\/wp-content\/uploads\/2021\/11\/lungs-destaques.png","datePublished":"2022-03-31T18:54:34+00:00","breadcrumb":{"@id":"https:\/\/sbpt.org.br\/portal\/anvisa-sotorasibe\/#breadcrumb"},"inLanguage":"pt-BR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/sbpt.org.br\/portal\/anvisa-sotorasibe\/"]}]},{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/sbpt.org.br\/portal\/anvisa-sotorasibe\/#primaryimage","url":"https:\/\/sbpt.org.br\/portal\/wp-content\/uploads\/2021\/11\/lungs-destaques.png","contentUrl":"https:\/\/sbpt.org.br\/portal\/wp-content\/uploads\/2021\/11\/lungs-destaques.png","width":350,"height":255},{"@type":"BreadcrumbList","@id":"https:\/\/sbpt.org.br\/portal\/anvisa-sotorasibe\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/sbpt.org.br\/portal\/"},{"@type":"ListItem","position":2,"name":"Anvisa aprova inibidor de muta\u00e7\u00f5es de KRAS G12C para c\u00e2ncer de pulm\u00e3o"}]},{"@type":"WebSite","@id":"https:\/\/sbpt.org.br\/portal\/#website","url":"https:\/\/sbpt.org.br\/portal\/","name":"sbpt.org.br","description":"Sociedade Brasileira de Pneumologia e Tisiologia","publisher":{"@id":"https:\/\/sbpt.org.br\/portal\/#organization"},"alternateName":"SBPT","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/sbpt.org.br\/portal\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pt-BR"},{"@type":"Organization","@id":"https:\/\/sbpt.org.br\/portal\/#organization","name":"sbpt.org.br","url":"https:\/\/sbpt.org.br\/portal\/","logo":{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/sbpt.org.br\/portal\/#\/schema\/logo\/image\/","url":"https:\/\/sbpt.org.br\/portal\/wp-content\/uploads\/2026\/10\/logo-sbpt.png","contentUrl":"https:\/\/sbpt.org.br\/portal\/wp-content\/uploads\/2026\/10\/logo-sbpt.png","width":512,"height":512,"caption":"sbpt.org.br"},"image":{"@id":"https:\/\/sbpt.org.br\/portal\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/pneumosbpt","https:\/\/x.com\/pneumosbpt","https:\/\/www.linkedin.com\/company\/pneumosbpt\/","https:\/\/www.instagram.com\/pneumosbpt\/","https:\/\/www.youtube.com\/user\/socbraspneumol"]},{"@type":"Person","@id":"https:\/\/sbpt.org.br\/portal\/#\/schema\/person\/adba7f33cf32721354590c6f0eb852d4","name":"Comunica\u00e7\u00e3o SBPT","image":{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/secure.gravatar.com\/avatar\/83068fab2f784f5c487104783a7006fb40e8fd85adc44189ac928b9e39fddad8?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/83068fab2f784f5c487104783a7006fb40e8fd85adc44189ac928b9e39fddad8?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/83068fab2f784f5c487104783a7006fb40e8fd85adc44189ac928b9e39fddad8?s=96&d=mm&r=g","caption":"Comunica\u00e7\u00e3o SBPT"},"url":"https:\/\/sbpt.org.br\/portal\/author\/anahelena\/"}]}},"_links":{"self":[{"href":"https:\/\/sbpt.org.br\/portal\/wp-json\/wp\/v2\/posts\/23180","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/sbpt.org.br\/portal\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/sbpt.org.br\/portal\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/sbpt.org.br\/portal\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/sbpt.org.br\/portal\/wp-json\/wp\/v2\/comments?post=23180"}],"version-history":[{"count":0,"href":"https:\/\/sbpt.org.br\/portal\/wp-json\/wp\/v2\/posts\/23180\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/sbpt.org.br\/portal\/wp-json\/wp\/v2\/media\/22168"}],"wp:attachment":[{"href":"https:\/\/sbpt.org.br\/portal\/wp-json\/wp\/v2\/media?parent=23180"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/sbpt.org.br\/portal\/wp-json\/wp\/v2\/categories?post=23180"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/sbpt.org.br\/portal\/wp-json\/wp\/v2\/tags?post=23180"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}